I recently read this: **Vision Life Sciences article on Chinese AI drug discovery** and was surprised by some of the numbers. It led me down a rabbit hole on Chinese biotech, and I ended up taking a position in the **Global X China Biotech ETF (2820 HK)**.
The thesis is not simply “AI will discover drugs faster.” What caught my attention is that AI may actually make China’s existing **wet-lab, CRO/CDMO and clinical-trial infrastructure more valuable**. AI can generate far more promising molecules, but somebody still needs to synthesise, test, validate and manufacture them.
Some facts that stood out to me:
\- China went from \~2% of global clinical trials in 2009 to roughly **32% in 2025**.
\- Chinese clinical development is significantly faster and cheaper than in the US.
\- Chinese biotech has rapidly become a major source of drugs licensed by Western Big Pharma.
\- China has built a deep ecosystem around companies such as **WuXi AppTec, WuXi Biologics, Pharmaron, Hengrui, Innovent and BeOne**.
\- Biotech, AI and innovative medicines are also explicit **Chinese state priorities**, with policy support now extending into R&D, healthcare data, licensing and international expansion.
\- China has built a deep ecosystem around companies such as **WuXi AppTec, WuXi Biologics, Pharmaron, Hengrui, Innovent and BeOne**.
\- Biotech, AI and innovative medicines are also explicit **Chinese state priorities**, with policy support now extending into R&D, healthcare data, licensing and international expansion.
So the potential flywheel is:
**AI → more viable molecules → faster/cheaper Chinese testing → more clinical data → more licensing to global pharma → more capital and better R&D.**
I normally prefer individual stocks over thematic ETFs. Here, though, an ETF made more sense to me because **(a)** I’m not a biotech expert, **(b)** individual drug pipelines are highly binary, and **(c)** I’m really betting on the ecosystem rather than one molecule/company.
I chose **2820 HK** because it covers both the **innovators** (BeOne, Innovent, Hengrui, Akeso etc.) and the **picks-and-shovels** (WuXi AppTec, WuXi Biologics, Pharmaron, Tigermed etc.), including mainland A-shares that some competing ETFs miss.
One caveat: the fund may use up to **50% synthetic exposure**, although currently it is almost entirely invested directly in securities. Normally that would bother me more, but I preferred its overall exposure.
The obvious risks are **US-China geopolitics, clinical failures, regulation/IP issues and valuation** — some of the leaders have already rerated significantly.
**Curious where people think this thesis breaks. Is China’s combination of AI + biotech infrastructure + clinical execution a durable competitive advantage, or are the recent numbers being extrapolated too far?**
